Recursion’s AI-Selected MEK Drug Cuts FAP Polyp Burden in Small Trial

Recursion’s AI-selected MEK drug cuts FAP polyp burden in small trial

Recursion Pharmaceuticals dropped phase 1b/2 results Monday for REC-4881, a MEK inhibitor it flagged through AI screens. In 12 older patients (55 years old and older) with familial adenomatous polyposis, the drug trimmed total polyp burden a median 43% after three months. The gains stuck around: 12 weeks off treatment, the median drop climbed to… The post Recursion’s AI-selected MEK drug cuts FAP polyp burden in small trial appeared first on Dru…

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks – Swaziland Online News

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks Leave a reply REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks […]

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks – Cape Verde Wire

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, […]